such as sitagliptin, vildagliptin, and teneligliptin.
6) DPP-4 inhibitors
were initially found to be associated with fewer cardiovascular events and less hypoglycemia than sulfonylureas, but were subsequently linked to an increased risk of hospitalization for heart failure.
Speaking during the ADA session, study investigator Dr John Buse (University of North Carolina School of Medicine, Chapel Hill) said the DPP-4 inhibitors
have been "embraced" by patients and physicians alike.
But further larger studies with more number of patients are needed to evaluate the magnitude of antidiabetic effects of DPP-4 inhibitors
However, these well conducted studies bring up some consideration about the use of DPP-4 inhibitors
in diabetic patients with RA.
The incretin class is composed of GLP-1 agonists and DPP-4 inhibitors
Compared with the patients who received a DPP-4 inhibitor
on top of metformin, those who received a sulfonylurea had an increased risk of both fatal and nonfatal cardiovascular disease (HR, 1.
Astra-Zeneca supported the CREST study and the sulfonylureas versus DPP-4 inhibitor
Since launching Januvia (sitagliptin) in 2006 as the first DPP-4 inhibitor
in the United States, Merck has continued to collaborate with academic and industry partners on advances in the care of patients with diabetes, and to research and develop innovative treatment options.
Kombiglyze is a combination of saxagliptin (also known as Onglyza), a DPP-4 inhibitor
, and metformin immediate-release (metformin IR), a biguanide.
Sitagliptin, which is currently developed by US pharmaceutical firm Merck, is an oral DPP-4 inhibitor
with a hypoglycemic mechanism different from the conventional agents.
Use caution in a patient with a history of angioedema with another DPP-4 inhibitor
because it is unknown whether such patients will be predisposed to angioedema with JANUVIA.